|
| Status |
Public on Dec 31, 2023 |
| Title |
Expression profiling in R/M HNSCC treated with immunotherapy (training set) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
In recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC) not amenable to salvage surgery or radiation, the overall survival remains unsatisfactory, and the patients often experience a huge burden of symptoms requiring treatments that could achieve objective response on the disease itself. Recently, treatment with immune checkpoint inhibitors (ICI) has shown survival benefit in randomized clinical trials both in the setting of platinum pre-treated patients and in patients at their first line of treatment, with the expression of PDL1 on the tumor. Despite the introduction of ICI, only a small subset of RM HNSCC patients achieves long-term survivorship. We aim at identifying predictors of outcome and evaluating a gene expression signature (Cl6-immunereactive) in patients treated with ICI therapy. Our data highlight the presence of biological underlying differences able to predict outcome following treatment with ICI for platinum-refractory RM-HNSCC.
|
| |
|
| Overall design |
This was a translational research on a single-arm, open-label, multicenter, phase IIIb clinical trial (NIVACTOR) in patients with Recurrent or Metastatic (RM) platinum-refractoy HNSCC treated with nivolumab (EudraCT Number: 2017-000562-30). The NIVACTOR study enrolled 127 R/M HNSCC patients to fulfill both clinical and translational endpoints. Whole transcriptome RNA profiling was feasible on 80 FFPE tissue specimens. There are no significant differences between the whole cohort and the subset used for the gene-expression profiling in terms of their gender, age, PS, smoking, primary tumor site, stage, site of metastatis, PDL1 status (TPS or CPS).
|
| |
|
| Contributor(s) |
De Cecco L |
| Citation(s) |
38290766 |
| |
| Submission date |
Sep 01, 2022 |
| Last update date |
Feb 14, 2024 |
| Contact name |
Loris De Cecco |
| E-mail(s) |
[email protected]
|
| Organization name |
IRCSS Istituto Nazionale Tumori
|
| Street address |
via Venezian 1
|
| City |
Milan |
| ZIP/Postal code |
20133 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL23126 |
[Clariom_D_Human] Affymetrix Human Clariom D Assay [transcript (gene) version] |
|
| Samples (80)
|
|
| This SubSeries is part of SuperSeries: |
| GSE212551 |
Expression profiling in R/M HNSCC treated with immunotherapy |
|
| Relations |
| BioProject |
PRJNA875946 |
Less...
More...